Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Pacira Pharmaceuticals

Share:
Related PCRX
Pacira Announces Data Reinforcing Benefits of EXPAREL for Postsurgical Pain Control Following Total Hip and Knee Replacement Surgery
Wedbush Securities Believes SH Data Bodes Well For Pacira Pharmaceuticals
The Vetr community has downgraded $PCRX to 3-Stars (Vetr)

In a report published Friday, Jefferies & Company reiterated its Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX), and raised its price target from $22.00 to $24.00.

Jefferies noted, “PCRX completed a strong round of financing ($110M ‘convert' at favorable terms) removing a financing overhang – we had modeled cash needs in '13 – and provides a clear runway to profitability in '14. Q4 pre-announced Exparel sales beat estimates and the Exparel commercial metrics bode very well and support our bullish sales estimates. We raise our PT to $24 based on Exparel trends and removal of financing risk.”

Pacira Pharmaceuticals closed on Thursday at $19.43.

Latest Ratings for PCRX

DateFirmActionFromTo
Mar 2015BarclaysMaintainsOverweight
Mar 2015Canaccord GenuityMaintainsBuy
Mar 2015BarclaysMaintainsOverweight

View More Analyst Ratings for PCRX
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (PCRX)

Around the Web, We're Loving...